Drug Trial News

RSS

Mayo Clinic and IBM plan to pilot Watson to begin research studies in cancer

Mayo Clinic and IBM today announced plans to pilot Watson, the IBM cognitive computer, to match patients more quickly with appropriate clinical trials, beginning with research studies in cancer. A proof-of-concept phase is currently underway.

9 Sep 2014

Agents targeting mitochondrial metabolism can have activity in leukemia

Results of a Phase I clinical trial showed that a new drug targeting mitochondrial function in human cancer cells was safe and showed some efficacy.

9 Sep 2014

New data from Boehringer's Phase III trial program evaluates efficacy of tiotropium in asthma patients

Boehringer Ingelheim today presented new data from the company's Phase III trial program (UniTinA-asthma®) evaluating tiotropium in asthma, including the first study assessing the efficacy and safety of tiotropium in adolescent patients with symptomatic asthma.

9 Sep 2014

Soligenix acquires novel orphan drug candidate for treatment of CTCL

Soligenix, Inc., a late-stage biopharmaceutical company developing products that address unmet medical needs in the areas of inflammation, oncology and biodefense, announced today the acquisition of a novel orphan drug candidate, known as SGX301 (synthetic hypericin).

8 Sep 2014

Peramivir drug safe, effective at alleviating influenza symptoms

An analysis of phase 2 and phase 3 clinical trials shows that a single injected dose of the neuraminidase inhibitor (NAI) peramivir is safe and effective at alleviating influenza symptoms, including fever and viral shedding, when administered within 48 hours of the onset of symptoms.

6 Sep 2014

Researchers to study effectiveness of atorvastatin in preventing heart problems in breast cancer patients

Wake Forest Baptist Medical Center has been awarded $4.4 million to conduct a multiple-site clinical trial testing the effectiveness of a statin drug in preventing cardiovascular events in women treated for breast cancer.

5 Sep 2014

Oncolytics Biotech completes randomized Phase 2 study of ovarian, fallopian tube cancer

Oncolytics Biotech Inc. today announced that patient enrollment has been completed in a randomized Phase 2 study of paclitaxel plus REOLYSIN® versus paclitaxel alone in patients with persistent or recurrent ovarian, fallopian tube or primary peritoneal cancer (GOG186H).

4 Sep 2014

Ascend Biopharmaceuticals provides update on clinical trial program for lead immunotherapy products

Ascend Biopharmaceuticals, a Melbourne-based immunotherapy company, has released an update on the clinical trial pipeline for its lead immunotherapy products treating basal cell carcinoma (BCC) and breast cancer.

4 Sep 2014

Novira completes Phase 1a clinical study of NVR-1221 for treatment of HBV infection

Novira Therapeutics, Inc., a privately held biopharmaceutical company developing novel therapies for curative treatment of chronic hepatitis B virus (HBV) infection, today announced successful completion of a Phase 1a clinical study of NVR-1221.

4 Sep 2014

Positive clinical data for first procedural therapy to treat type 2 diabetes from Fractyl

Fractyl Laboratories Inc. today announced positive clinical data for the first procedural therapy to directly treat the underlying digestive causes of insulin resistance in patients with uncontrolled type 2 diabetes.

4 Sep 2014

F2G begins F901318 Phase I clinical study for treatment of aspergillus infections

F2G Limited, the antifungal research and development company today announced a major milestone in the development of its novel IV/ oral systemic antifungal (F901318) with the commencement of a Phase I clinical study.

4 Sep 2014

Ludwig, CRI collaborate with VentiRx to conduct clinical trial with motolimod and immunotherapy agents

The nonprofits Ludwig Cancer Research (Ludwig) and the Cancer Research Institute (CRI) announced today an agreement with VentiRx Pharmaceuticals Inc., a clinical stage biopharmaceutical company, to conduct a clinical trial with motolimod (VTX-2337) combined with other immunotherapy agents available to Ludwig and CRI through other industry partnerships.

4 Sep 2014

Clinical trial to assess safety and efficacy of novel monoclonal antibody for CLL patients

Researchers at the University of California, San Diego School of Medicine, in partnership with the California Institute for Regenerative Medicine (CIRM) and Celgene Corporation, a New Jersey-based biopharmaceutical company, have launched a phase 1 human clinical trial to assess the safety and efficacy of a novel monoclonal antibody for patients with chronic lymphocytic leukemia (CLL).

4 Sep 2014

Clinical studies to treat unmet medical need post-transplantation

A class of biotechnology drugs called monoclonal antibodies is now being tested in clinical studies to treat an unmet medical need post-transplantation, called delayed graft function

3 Sep 2014

ANP reports primary efficacy results from ATL1103 Phase II trial in patients with acromegaly

Antisense Therapeutics Limited is pleased to report the primary efficacy results from its Phase II clinical trial of ATL1103 in patients with the potentially life threatening growth disorder, acromegaly.

2 Sep 2014

XBiotech reports interim results from Phase III study for anti-cancer agent Xilonix

XBiotech announced today interim results from its fast-tracked Phase III study being conducted in the US for its anti-cancer agent Xilonix.

2 Sep 2014

MEI Pharma completes patient enrollment in Pracinostat Phase II trial for treatment of MDS

MEI Pharma, Inc., an oncology company focused on the clinical development of novel therapies for cancer, announced today that it has completed enrollment in a randomized Phase II clinical trial of its lead investigational drug candidate Pracinostat in combination with azacitidine in patients with previously untreated intermediate-2 or high-risk myelodysplastic syndrome (MDS).

2 Sep 2014

Ampio updates phase III, multicenter, double-blind STEP study of Ampion for knee osteoarthritis

Ampio Pharmaceuticals, Inc. today announced an update on the phase III, multicenter, double-blind STEP study of Ampion™ for osteoarthritis of the knee.

2 Sep 2014

Soligenix announces promising preliminary results from study on ricin toxin vaccine

Soligenix, Inc., a clinical stage biopharmaceutical company focused on developing products to treat serious inflammatory diseases where there remains an unmet medical need, as well as developing several biodefense vaccines and therapeutics, announced today promising preliminary results from a preclinical study with its ricin toxin vaccine RiVax™, in a non-human primate (NHP) lethal aerosol exposure model.

2 Sep 2014

Experimental agent TRO40303 ineffective in patients with heart attack

The administration of an experimental agent known as TRO40303 to patients who have had a heart attack, with the hope of preventing tissue damage when impaired blood flow is corrected (reperfusion), was disappointingly ineffective according to results of a European study of patients with acute ST-elevation myocardial infarction (STEMI) presented today as a Hot Line the ESC Congress 2014 with simultaneous publication in the European Heart Journal.

1 Sep 2014

Drug Trial News

Mayo Clinic and IBM plan to pilot Watson to begin research studies in cancer

Agents targeting mitochondrial metabolism can have activity in leukemia

New data from Boehringer's Phase III trial program evaluates efficacy of tiotropium in asthma patients

Soligenix acquires novel orphan drug candidate for treatment of CTCL

Peramivir drug safe, effective at alleviating influenza symptoms

Researchers to study effectiveness of atorvastatin in preventing heart problems in breast cancer patients

Oncolytics Biotech completes randomized Phase 2 study of ovarian, fallopian tube cancer

Ascend Biopharmaceuticals provides update on clinical trial program for lead immunotherapy products

Novira completes Phase 1a clinical study of NVR-1221 for treatment of HBV infection

Positive clinical data for first procedural therapy to treat type 2 diabetes from Fractyl

F2G begins F901318 Phase I clinical study for treatment of aspergillus infections

Ludwig, CRI collaborate with VentiRx to conduct clinical trial with motolimod and immunotherapy agents

Clinical trial to assess safety and efficacy of novel monoclonal antibody for CLL patients

Clinical studies to treat unmet medical need post-transplantation

ANP reports primary efficacy results from ATL1103 Phase II trial in patients with acromegaly

XBiotech reports interim results from Phase III study for anti-cancer agent Xilonix

MEI Pharma completes patient enrollment in Pracinostat Phase II trial for treatment of MDS

Ampio updates phase III, multicenter, double-blind STEP study of Ampion for knee osteoarthritis

Soligenix announces promising preliminary results from study on ricin toxin vaccine

Experimental agent TRO40303 ineffective in patients with heart attack

Small solutions for big problems in drug discovery and delivery

Professor Nancy Ip: Pioneering New Paths in Neurodegenerative Therapy

Utilizing process Raman in optimizing cultivated meat production

Latest News